Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
RecruitingOBSERVATIONAL
Enrollment
70
Participants
Timeline
Start Date
March 24, 2020
Primary Completion Date
December 24, 2024
Study Completion Date
March 24, 2025
Conditions
Non-small Cell Lung Cancer
Trial Locations (1)
410013
RECRUITING
Yongchang Zhang, Changsha
All Listed Sponsors
lead
Hunan Province Tumor Hospital
OTHER
NCT04322591 - Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial | Biotech Hunter | Biotech Hunter